The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Mantle Cell Lymphoma
Abstract
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older patients. In particular, greater depth of understanding of the molecular pathophysiology of MCL has resulted in an explosion of specifically targeted new efficacious agents. In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton’s tyrosine kinase inhibitor ibrutinib. We review recent advances in the understanding of MCL biology and outline our recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationG1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationKochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Self-citationHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Self-citationLannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147025 · Cited by 622
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Self-citationTreatment of Older Patients with Mantle-Cell Lymphoma
Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200920 · Cited by 520
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Beà, S., Valdés-Mas, R., Navarro, A., Salaverria, I., Martín-Garcia, D., Jares, P., Giné, E., Pinyol, M., Royo, C., Nadeu, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314608110 · Cited by 513
Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases
Argatoff, L. H., Connors, J. M., Klasa, R. J., Horsman, D. E., & Gascoyne, R. D. (1997) · Blood · doi:10.1182/blood.v89.6.2067 · Cited by 497
Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.-P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016725 · Cited by 467
Self-citationGenomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
Fernàndez, V., Salamero, O., Espinet, B., Solé, F., Royo, C., Navarro, A., Camacho, F., Beà, S., Hartmann, E., Amador, V., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3419 · Cited by 463
Rummel, M. J., Al-Batran, S. E., Kim, S.-Z., Welslau, M., Hecker, R., Kofahl-Krause, D., Josten, K.-M., Dürk, H., Rost, A., Neise, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.100 · Cited by 441
Follicular lymphoma: prognostic factors for response and survival.
Gallagher, C. J., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M. A., Dhaliwal, H. S., Malpas, J. S., & Lister, T. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1470 · Cited by 425
Yang, Z.-Z., Novak, A. J., Stenson, M. J., Witzig, T. E., & Ansell, S. M. (2006) · Blood · doi:10.1182/blood-2005-08-3376 · Cited by 420
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
Kochenderfer, J. N., Feldman, S. A., Zhao, Y., Xu, H., Black, M. A., Morgan, R. A., Wilson, W. H., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ac6138 · Cited by 408
Mozos, A., Royo, C., Hartmann, E., De Jong, D., Baro, C., Valera, A., Fu, K., Weisenburger, D. D., Delabie, J., Chuang, S.-S., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.010264 · Cited by 398
Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R., Polikoff, J. A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Molecular pathogenesis of mantle cell lymphoma
Jares, P., Colomer, D., & Campo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61272 · Cited by 382
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Fu, K. (2005) · Blood · doi:10.1182/blood-2005-04-1753 · Cited by 346
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R. R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6121 · Cited by 339
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Kridel, R., Meissner, B., Rogic, S., Boyle, M., Telenius, A., Woolcock, B., Gunawardana, J., Jenkins, C., Cochrane, C., Ben-Neriah, S., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391474 · Cited by 338
Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn656 · Cited by 336
Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70128-2 · Cited by 336
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Self-citationTranscriptional role of cyclin D1 in development revealed by a genetic-proteomic screen
Bienvenu, F., Jirawatnotai, S., Elias, J. E., Meyer, C. A., Mizeracka, K., Marson, A., Frampton, G. M., Cole, M. F., Odom, D. T., Odajima, J., et al. (2010) · Nature · doi:10.1038/nature08684 · Cited by 276
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273
Delarue, R., Haioun, C., Ribrag, V., Brice, P., Delmer, A., Tilly, H., Salles, G., Van Hoof, A., Casasnovas, O., Brousse, N., et al. (2013) · Blood · doi:10.1182/blood-2011-09-370320 · Cited by 270
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
Romaguera, J. E., Medeiros, L. J., Hagemeister, F. B., Fayad, L. E., Rodriguez, M. A., Pro, B., Younes, A., McLaughlin, P., Goy, A., Sarris, A. H., et al. (2003) · Cancer · doi:10.1002/cncr.11096 · Cited by 269
Navarro, A., Clot, G., Royo, C., Jares, P., Hadzidimitriou, A., Agathangelidis, A., Bikos, V., Darzentas, N., Papadaki, T., Salaverria, I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1615 · Cited by 256
Younes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J., Vermeulen, J., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 254
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537555 · Cited by 252
Romaguera, J. E., Fayad, L. E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M. A., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08228.x · Cited by 245
Self-citationHabermann, T. M., Lossos, I. S., Justice, G., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin‐Haynes, A., Takeshita, K., Pietronigro, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07626.x · Cited by 244
Aggarwal, P., Vaites, L. P., Kim, J. K., Mellert, H., Gurung, B., Nakagawa, H., Herlyn, M., Hua, X., Rustgi, A. K., McMahon, S. B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.012 · Cited by 242
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Zhang, J., Jima, D., Moffitt, A. B., Liu, Q., Czader, M., Hsi, E. D., Fedoriw, Y., Dunphy, C. H., Richards, K. L., Gill, J. I., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517177 · Cited by 236
Wang, M. L., Lee, H., Chuang, H., Wagner-Bartak, N., Hagemeister, F., Westin, J., Fayad, L., Samaniego, F., Turturro, F., Oki, Y., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00438-6 · Cited by 216
Self-citationKirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, V., Matsuoka, D., Pulone, B., Rotter, A. J., Espinoza-Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1398 · Cited by 213
Morschhauser, F. A., Cartron, G., Thieblemont, C., Solal-Céligny, P., Haioun, C., Bouabdallah, R., Feugier, P., Bouabdallah, K., Asikanius, E., Lei, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9585 · Cited by 206
Ansell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., et al. (2008) · Cancer · doi:10.1002/cncr.23580 · Cited by 203
Kurtova, A. V., Tamayo, A. T., Ford, R. J., & Burger, J. A. (2009) · Blood · doi:10.1182/blood-2008-10-185827 · Cited by 199
Vegliante, M. C., Palomero, J., Pérez‐Galán, P., Roué, G., Castellano, G., Navarro, A., Clot, G., Moros, A., Suárez-Cisneros, H., Beà, S., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438937 · Cited by 177
Cheah, C. Y., Chihara, D., Romaguera, J. E., Fowler, N. H., Seymour, J. F., Hagemeister, F. B., Champlin, R. E., & Wang, M. L. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv111 · Cited by 177
Self-citationVisco, C., Finotto, S., Zambello, R., Paolini, R., Menin, A., Zanotti, R., Zaja, F., Semenzato, G., Pizzolo, G., D'Amore, E. S. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9842 · Cited by 173
Rizzatti, E. G., Falcão, R. P., Panepucci, R. A., Proto‐Siqueira, R., Anselmo‐Lima, W. T., Okamoto, O. K., & Zago, M. A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05630.x · Cited by 164
Delfau-Larue, M.-H., Klapper, W., Berger, F., Jardin, F., Briere, J., Salles, G., Casasnovas, O., Feugier, P., Haioun, C., Ribrag, V., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628792 · Cited by 161
Ansell, S. M., Tang, H. J., Kurtin, P. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70062-6 · Cited by 154
Meadows, S. A., Vega, F., Kashishian, A., Johnson, D., Diehl, V., Miller, L. L., Younes, A., & Lannutti, B. J. (2011) · Blood · doi:10.1182/blood-2011-10-386763 · Cited by 152
Sánchez‐Aguilera, A. (2006) · Blood · doi:10.1182/blood-2005-12-5125 · Cited by 143
Abrahamsson, A., Albertsson‐Lindblad, A., Brown, P. D. N., Baumgartner-Wennerholm, S., Pedersen, L. M., d’Amore, F., Nilsson‐Ehle, H., Jensen, P., Pedersen, M., Geisler, C. H., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559930 · Cited by 136
Maddocks, K. J., Christian, B. A., Jaglowski, S. M., Flynn, J. M., Jones, J. A., Porcu, P., Wei, L., Jenkins, C., Lozanski, G., Byrd, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-597914 · Cited by 133
Nordström, L., Sernbo, S., Edén, P., Grønbæk, K., Kolstad, A., Räty, R., Karjalainen, M., Geisler, C. H., Ralfkiaer, E. M., Sundström, C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12854 · Cited by 133
Zhang, L., Yang, J., Qian, J., Li, H., Romaguera, J. E., Kwak, L. W., Wang, M. L., & Yi, Q. (2012) · Blood · doi:10.1182/blood-2012-04-424630 · Cited by 133
Self-citationZinzani, P. L., Vose, J. M., Czuczman, M. S., Reeder, C. B., Haïoun, C., Polikoff, J. A., Tilly, H., Zhang, L. F., Prandi, K., Li, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt366 · Cited by 122
Kiaii, S., Clear, A. J., Ramsay, A. G., Davies, D. C., Sangaralingam, A., Lee, A. R. I., Calaminici, M., Neuberg, D. S., & Gribben, J. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2137 · Cited by 120
Palomero, J., Vegliante, M. C., Rodríguez, M. L., Eguileor, Á., Castellano, G., Planas‐Rigol, E., Jares, P., Ribera‐Cortada, I., Cid, M. C., Campo, E., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569566 · Cited by 112
Barışta, İ., Romaguera, J. E., & Cabanillas, F. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00255-2 · Cited by 107
Moros, A., Rodríguez, V., Saborit-Villarroya, I., Montraveta, A., Balsas, P., Sandy, P., Martı́nez, A., Wiestner, A. U., Normant, E., Campo, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.106 · Cited by 104
LaCasce, A. S., Vandergrift, J. L., Rodriguez, M. A., Abel, G. A., Crosby, A. L., Czuczman, M. S., Nademanee, A. P., Blayney, D. W., Gordon, L. I., Millenson, M. M., et al. (2012) · Blood · doi:10.1182/blood-2011-07-369629 · Cited by 97
Davids, M. S., Seymour, J. F., Gerecitano, J. F., Kahl, B. S., Pagel, J. M., Wierda, W. G., Anderson, M. A., Rudersdorf, N. K., Gressick, L. A., Montalvo, N. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8522 · Cited by 92
Self-citationGesk, S., Klapper, W., Martín-Subero, J. I., Nagel, I., Harder, L., Fu, K., Bernd, H., Weisenburger, D. D., Parwaresch, R. M., & Siebert, R. (2006) · Blood · doi:10.1182/blood-2006-01-0015 · Cited by 87
Heider, U., Kaiser, M., Sterz, J., Zavrski, I., Jakob, C., Fleissner, C., Eucker, J., Possinger, K., & Sezer, O. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00546.x · Cited by 82
Wang, L., Qian, J., Lu, Y., Li, H., Bao, H., He, D., Liu, Z., Zheng, Y., He, J., Li, Y., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.071340 · Cited by 70
Hipp, S., Ringshausen, I., Oelsner, M., Bogner, C., Peschel, C., & Decker, T. W. (2005) · PubMed · Cited by 68
Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E. M., Yang, D. T., Advani, R. H., Horning, S. J., & Kahl, B. S. (2014) · Blood · doi:10.1182/blood-2013-08-523845 · Cited by 66
Dietrich, S., Boumendil, A., Finel, H., Avivi, I. M., Volin, L., Cornelissen, J. J., Jarosinska, R. J., Schmid, C., Finke, J., Stevens, W. B. C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu097 · Cited by 66
Burger, J. A., & Ford, R. J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.006 · Cited by 65
Watanabe, T., Kato, H., Kobayashi, Y., Yamasaki, S., Morita‐Hoshi, Y., Yokoyama, H., Morishima, Y., Ricker, J. L., Otsuki, T., Miyagi‐Maesima, A., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01360.x · Cited by 64
Qian, Z., Zhang, L., Cai, Z., Sun, L., Wang, H., Yi, Q., & Wang, M. L. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.09.027 · Cited by 62
Self-citationLenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma
Song, K., Herzog, B. H., Sheng, M., Fu, J., McDaniel, J. M., Ruan, J., & Xia, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0750 · Cited by 62
Witzig, T. E., Geyer, S. M., Kurtin, P. J., Colgan, J. P., Inwards, D. J., Micallef, I. N., LaPlant, B. R., Michalak, J. C., Salim, M., Dalton, R. J., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801993470 · Cited by 59
Plesner, T., Arkenau, H., Lokhorst, H. M., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Ahmadi, T., et al. (2014) · Blood · doi:10.1182/blood.v124.21.84.84 · Cited by 49
Meggendorfer, M., Kern, W., Haferlach, C., Haferlach, T., & Schnittger, S. (2013) · Leukemia · doi:10.1038/leu.2013.141 · Cited by 43
Schuster, S. J., Svoboda, J., Nasta, S. D., Porter, D. L., Mato, A. R., Shah, G., Landsburg, D. J., Chong, E. A., Lacey, S. F., Melenhorst, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8516 · Cited by 39
Wang, M. L., Popplewell, L. L., Collins, R. H., Winter, J. N., Goy, A. H., Kaminski, M. S., Bartlett, N. L., Johnston, P. B., LISTER, J. W., Fanning, S. R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12780 · Cited by 36
Self-citationWang, M. L., Fayad, L., Cabanillas, F., Hagemeister, F. B., McLaughlin, P. J., Rodriguez, M. A., Kwak, L. W., Zhou, Y., Kantarjian, H. M., & Romaguera, J. E. (2008) · Cancer · doi:10.1002/cncr.23880 · Cited by 33
Self-citationLenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective
Desai, M., Newberry, K. J., Ou, Z., Wang, M. L., & Zhang, L. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532124 · Cited by 26
Self-citationEvens, A. M., Vose, J. M., Harb, W. A., Gordon, L. I., Langdon, R. M., Grant, B., Sprague, J. R., Plasencia, C., Sirisawad, M., Yue, J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.55.55 · Cited by 24
Trněný, M., Lamy, T., Walewski, J. A., Jurczak, W. J., Belada, D., Mayer, J., Radford, J. A., Alexeeva, J., Шевкетович, О. Д., Biyukov, T. N., et al. (2014) · Blood · doi:10.1182/blood.v124.21.626.626 · Cited by 22
Morschhauser, F., Bouabdallah, K., Stilgenbauer, S., Thieblemont, C., Wolf, M., de Guibert, S., Zettl, F., Hahka-Kemppinen, M., Xiaohui Wang, D., Brueck, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3067.3067 · Cited by 20
Till, B. G., Li, H., Bernstein, S. H., Fisher, R. I., Burack, R., Rimsza, L. M., Floyd, J. D., DaSilva, M. A., Moore, D. F., LeBlanc, M. L., et al. (2014) · Blood · doi:10.1182/blood.v124.21.149.149 · Cited by 11
Cited by
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Self-citationRole of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Damaj, G., Gastinne, T., Ribrag, V., Feugier, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701769 · Cited by 416
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
Metadata
- Authors
- Cheah, C. Y., Seymour, J. F., & Wang, M. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-04-10
- Volume
- 34
- Issue
- 11
- Pages
- 1256-1269
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2238159161
- Cited by
- 264
- References
- 104
- FWCI
- 33.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.